NSC-631570 is the product of the reaction of different alkaloids from Chelidonium majus L.Numerous preclinical and clinical studies have proven its efficacy and safety (Ernst et al, 2005).The aim of this study was to analyse the results of using NSC-631570 in treatment of children.A total of 203 advanced-stage cancer patients among them 14 children were treated with NSC-631570 in doses of 0.3 mg/kg 3 times a week for 3 week.80.3% of patients had remission (Aschhoffet al, 2000).5 children with severe stages of malignant tumors such as recurrent astrocytoma of the optic nerve, neuroblastoma, Ewings sarcoma, xeroderma pigmentosum and tuberous sclerosis with subependymal giant cell astrocytoma received NSC-631570 at various concentration as a monotherapy and in combination with hyperthermia and surgery.In all 5 children occurred complete or partial remission without side effects (Steinacker et al, 1996, Aschhoff et al, 1998, 2003, Nowicki et al, 2003).Considering that NSC-631570 also has immunomodulatory properties, safe for normal cells and its therapeutic index is 1250 (Sotomayor et al, 1992), was performed the studies of its efficacy in children with immunosuppressive conditions after Chernobyl disaster.38 children with recurrent respiratory diseases aged 3 to 14 years receive NSC-631570 in the total dose of 35 ml.The results of this study identify the immunomodulatory efficacy ofNSC-631570 (Zahriychuk,2003).Another study included a total of 40 children with recurrent bronchopulmonary disorders aged 7-18 years.It was identified the normalization of the clinical blood and respiratory parameters.Side effects of treatment were not available (Kazmirchuk et al 2003).So overall of 19 children with malignant tumors and 78 with recurrent respiratory diseases received the treatment with NSC-631570.The results were the complete and partial remission of disease, normalization the parameters of the immune system and clinical status of children.The negative effects ofNSC-631570 were absent.